Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Italy
· Delayed Price · Currency is EUR 52.15
-0.35 (-0.67%)
May 9, 2025, 5:35 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Specialty & Primary Care | 1.51B |
Log In |
Log In |
Log In |
Log In |
| Specialty & Primary Care Growth | 10.24% |
Log In |
Log In |
Log In |
Log In |
| Rare Diseases | 833.86M |
Log In |
Log In |
Log In |
Log In |
| Rare Diseases Growth | 16.67% |
Log In |
Log In |
Log In |
Log In |
| Urology and Uro-Oncology | 399.94M |
Log In |
Log In |
Log In |
Log In |
| Urology and Uro-Oncology Growth | 42.65% |
Log In |
Log In |
Log In |
Log In |
| Cardiovascular | 385.21M |
Log In |
Log In |
Log In |
Log In |
| Cardiovascular Growth | 5.47% |
Log In |
Log In |
Log In |
Log In |
| Gastrointestinal | 217.50M |
Log In |
Log In |
Log In |
Log In |
| Gastrointestinal Growth | -0.81% |
Log In |
Log In |
Log In |
Log In |
| Cough and Cold | 137.28M |
Log In |
Log In |
Log In |
Log In |
| Cough and Cold Growth | 0.12% |
Log In |
Log In |
Log In |
Log In |
| Other Treatment Areas | 309.31M |
Log In |
Log In |
Log In |
Log In |
| Other Treatment Areas Growth | -0.74% |
Log In |
Log In |
Log In |
Log In |
| Endocrinology | 321.69M |
Log In |
Log In |
Log In |
Log In |
| Endocrinology Growth | 32.75% |
Log In |
Log In |
Log In |
Log In |
| Metabolic and Other Areas | 258.94M |
Log In |
Log In |
Log In |
Log In |
| Metabolic and Other Areas Growth | -4.64% |
Log In |
Log In |
Log In |
Log In |
| Oncology | 253.23M |
Log In |
Log In |
Log In |
Log In |
| Oncology Growth | 26.08% |
Log In |
Log In |
Log In |
Log In |
| Pharmaceutical Chemicals | 58.47M |
Log In |
Log In |
Log In |
Log In |
| Pharmaceutical Chemicals Growth | 8.21% |
Log In |
Log In |
Log In |
Log In |
| Zanidip | - |
Log In |
Log In |
Log In |
Log In |
| Zanidip Growth | - |
Log In |
Log In |
Log In |
Log In |
| Zanipress | - |
Log In |
Log In |
Log In |
Log In |
| Zanipress Growth | - |
Log In |
Log In |
Log In |
Log In |
| Urorec | - |
Log In |
Log In |
Log In |
Log In |
| Urorec Growth | - |
Log In |
Log In |
Log In |
Log In |
| Livazo | - |
Log In |
Log In |
Log In |
Log In |
| Livazo Growth | - |
Log In |
Log In |
Log In |
Log In |
| Drugs for Rare Diseases | - |
Log In |
Log In |
Log In |
Log In |
| Drugs for Rare Diseases Growth | - |
Log In |
Log In |
Log In |
Log In |
| Seloken/Logimax | - |
Log In |
Log In |
Log In |
Log In |
| Seloken/Logimax Growth | - |
Log In |
Log In |
Log In |
Log In |
| Other Corporate Products | - |
Log In |
Log In |
Log In |
Log In |
| Other Corporate Products Growth | - |
Log In |
Log In |
Log In |
Log In |
| OTC | - |
Log In |
Log In |
Log In |
Log In |
| OTC Growth | - |
Log In |
Log In |
Log In |
Log In |
| Local Product Portfolios | - |
Log In |
Log In |
Log In |
Log In |
| Local Product Portfolios Growth | - |
Log In |
Log In |
Log In |
Log In |
| Other Product | - |
Log In |
Log In |
Log In |
Log In |
| Other Product Growth | - |
Log In |
Log In |
Log In |
Log In |
| Eligard | - |
Log In |
Log In |
Log In |
Log In |
| Eligard Growth | - |
Log In |
Log In |
Log In |
Log In |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Specialty & Primary Care Operating Income | 426.73M |
Log In |
Log In |
Log In |
Log In |
| Specialty & Primary Care Operating Income Growth | 9.91% |
Log In |
Log In |
Log In |
Log In |
| Rare Diseases Operating Income | 212.13M |
Log In |
Log In |
Log In |
Log In |
| Rare Diseases Operating Income Growth | 24.95% |
Log In |
Log In |
Log In |
Log In |
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Specialty & Primary Care EBITDA | 524.44M |
Log In |
Log In |
Log In |
Log In |
| Specialty & Primary Care EBITDA Growth | 12.23% |
Log In |
Log In |
Log In |
Log In |
| Rare Diseases EBITDA | 341.33M |
Log In |
Log In |
Log In |
Log In |
| Rare Diseases EBITDA Growth | 12.89% |
Log In |
Log In |
Log In |
Log In |
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Italy Revenue | 336.26M |
Log In |
Log In |
Log In |
Log In |
| Italy Revenue Growth | 6.04% |
Log In |
Log In |
Log In |
Log In |
| International Revenue | 2.01B |
Log In |
Log In |
Log In |
Log In |
| International Revenue Growth | 13.60% |
Log In |
Log In |
Log In |
Log In |
| Europe Revenue | 1.65B |
Log In |
Log In |
Log In |
Log In |
| Europe Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Asia and Oceania Revenue | 156.01M |
Log In |
Log In |
Log In |
Log In |
| Asia and Oceania Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| America Revenue | 477.46M |
Log In |
Log In |
Log In |
Log In |
| America Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Africa Revenue | 58.03M |
Log In |
Log In |
Log In |
Log In |
| Africa Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Specialty & Primary Care Like-For-Like Growth | 5.70% |
Log In |
Log In |
Log In |
Log In |
| Rare Diseases Like-For-Like Growth | 15.70% |
Log In |
Log In |
Log In |
Log In |
| Total Like-For-Like Growth | 9.20% |
Log In |
Log In |
Log In |
Log In |